Business Wire

DVB Bank’s Aviation Investment and Asset Management Business to Be Acquired by SVPGlobal and EnTrust Global

Share

The Blue Sky Aviation strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, and funds managed by Strategic Value Partners, LLC and its affiliates ("SVPGlobal"), a global investment firm, have today announced that they have entered into a definitive agreement to acquire the Aviation Investment and Asset Management business (the “Business”) from DVB Bank Group. The transaction is expected to close during the first half of 2021.

The Business, one of the top 10 aviation service companies globally, will be acquired through a newly incorporated UK company, Deucalion Aviation Limited (“Deucalion” or the “Company”). Today, the Business is a global aviation management platform that provides comprehensive turnkey solutions for financial investors looking to deploy capital in aircraft assets, through origination, structuring, execution, fund management and a full-fledged range of servicing activities, including aircraft remarketing, technical management, lease management and consultancy. The 45-strong team manages approximately 160 aircraft on lease to more than 80 airlines globally, representing approximately $5 billion in total asset value.

EnTrust and SVPGlobal’s investment is expected to provide the support required by the existing management team to build on its international growth strategy and explore complementary opportunities arising from the current aviation industry dislocation.

Deucalion, which will be led jointly by Jon Skirrow and Stephan Sayre, will be acquired through a joint venture formed between EnTrust and SVPGlobal, utilising the two firms’ complementary expertise. Senior members of the EnTrust Blue Sky Aviation and SVPGlobal teams have worked together on various transactions over the past 15 years.

Jon Skirrow said: “We are delighted to be partnering with EnTrust and SVPGlobal, following many successful years with DVB Bank Group. This new investment will support us in capitalizing on our strong growth trajectory, and we look forward to continuing to provide our world-leading services to our clients as we embark on the next stage of our development.”

Stephan Sayre added: “EnTrust and SVPGlobal, who share our vision of the opportunities in this sector today and in the long term, enable us not only to reinforce our commitment to providing best-in-class service for our clients, but also to significantly strengthen our offering of a broad array of innovative financing solutions to airline and leasing clients globally in the current environment.”

Victor Khosla, Founder & CIO of SVPGlobal, said: “This is an innovative platform with world class aviation expertise and an excellent track record in managing complex, large and unique projects across diversified asset types and structures over the last 17 years. Our investment as part of this joint venture with EnTrust is a testament to the sizeable market opportunity set we see ahead for the business.”

John Morabito, Senior Managing Director and Portfolio Manager of EnTrust Global’s Blue Sky Aviation strategy, said: “As we continue to build a multi-faceted, relative value investment platform in the aviation industry, this acquisition enhances EnTrust’s Blue Sky Aviation strategy with the full service capabilities critical to providing a wide offering of solutions to constituents within the market. We look forward to the opportunity to partner with SVPGlobal and the talented DVB management team, with whom our team has a long-standing relationship.”

About DVB

DVB Bank SE is a financial services provider specialising in international transport finance. With 329 employees and offices worldwide, the Bank manages a loan portfolio worth €3.9 billion. As an affiliate of DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, DVB is part of Germany's second-largest banking group. Please visit our website www.dvbbank.com for additional information.

About EnTrust Global

EnTrust Global is a leading alternative asset management firm with approximately $19 billion in total assets*. Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 47 countries and has approximately $10 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 11 offices worldwide and is headquartered in New York and London.

*As of September 30, 2020. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.

About Strategic Value Partners

SVPGlobal is a global investment firm with approximately $11 billion in assets under management. The firm, established by Victor Khosla in 2001, has 127 employees, including 49 investment professionals, across its main offices in Greenwich (CT), London and Tokyo. Learn more at www.svpglobal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

DVB
Stephan Sayre
Stephan.Sayre@dvbbank.com
+44 207 2564 344

Jon Skirrow
Jon.Skirrow@dvbbank.com
+44 207 2564 430

EnTrust Global
Hiltzik Strategies
Meghan Kilkenny, Chris Cunningham
EnTrust@hstrategies.com
+1 (212) 792-9338

SVPGlobal Europe
Greenbrook Communications
James Madsen, Mikaela Murekian, Fanni Bodri
svp@greenbrookpr.com
+44 20 7952 2000

SVPGlobal – North America
Kekst CNC
Todd Fogarty, Richard Goldman
SVPGlobal@kekstcnc.com
+1 (212) 521-4800

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye